Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The UK's medicines regulator has warned NHS healthcare staff about an increased risk of a condition affecting the nerves in ...

Researchers found that older adults who received AS01-adjuvanted shingles or RSV vaccines had a significantly lower risk of ...

The UK’s drugs regulator has advised healthcare professionals to alert RSV vaccine recipients to Guillain-Barré syndrome symptoms, although the risk remains low.

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory syncytial virus (RSV) is associated with a 29% reduction in dementia risk in ...

It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant stimulates cells of the immune system that could help protect the brain ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

Recent studies have shown convincingly that vaccines against shingles (Herpes zoster) reduce the risk of dementia.

A new study from the University of Oxford has revealed a surprising benefit of the respiratory syncytial virus (RSV) vaccine: ...

AREXVY is indicated for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older, as well as individuals 50 through 59 years of age who are ...

AREXVY recommended for adults aged 50-59 at increased risk for severe RSV disease by US Advisory Committee on Immunization Practices ...